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umerous studies have concluded that appropriate use of medications can reduce the mortality and morbidity of hypercholesterolemia. 1-3 Although in studies each participant is assumed to take medications as prescribed in the protocol, adherence to drug therapy is often suboptimal. Poor adherence to physician treatment recommendations is an increasingly recognized cause of adverse outcomes and increased healthcare costs. 4 Poor adherence is also said to account for up to two-thirds of preventable hospital admissions of patients with cardiovascular disease. 5- 7 The clinical importance of assessing patient adherence has been recognized in both general medicine and cardiology. 8 Poor adherence limits the effectiveness of proven treatments, resulting in lost opportunities to reduce mortality and readmission rates.
Historically, both the Coronary Drug Project 9 and the Beta Blocker in Heart Attack Trial 10 demonstrated that improved adherence was associated with improved survival. Furthermore, in an intention-to-treat analysis, patients with a high degree of adherence with randomized administration of medication demonstrated a substantial increase in risk reduction compared with that achieved by those with poor adherence. 11 Discontinuation of medication was an independent risk factor for higher mortality with a hazard ratio (HR) of 3.8 for Importance of Adherence to EPA Therapy survivors of acute myocardial infarction (AMI). 12 In the case of warfarin, time to fatal coronary event was twice as long in those fully compliant with treatment as in those who were non-compliant. 13 The clinical importance of adherence to treatment has also been demonstrated in patients with heart failure. 14- 16 A meta-analysis of data from approximately 20,000 patients further demonstrated that good adherence to drug therapy was associated with lower mortality than was poor adherence. 17 Adherence to medication refers to the extent of conformity with recommendations made concerning day-to-day treatment by a provider with respect to timing, dosage, and frequency. 18 However, assessment of adherence to medication is difficult. Self-reporting, counting of pills, and global reporting are the 3 major methods used to assess adherence. 17 Although self-reporting of information provides a measure of adherence, it may not accurately represent changes in adherence over time. 19 To avoid this limitation, our study used the eicosapentaenoic acid (EPA) concentration, an objective parameter that can be used to determine the accuracy of selfreporting by patients.
This article focuses on adherence to medication and cardiovascular outcomes in patients with hypercholesterolemia prescribed EPA and/or statin during JELIS (Japan EPA Lipid Intervention Study). 3 It also reports important predictors of improved adherence.
Methods

Participants
The design and main results of JELIS have been previously published. 3, 20 JELIS was an open-label, randomized controlled trial comparing the effects of EPA and statin (EPA group) with statin alone (control group) in patients with hypercholesterolemia. All patients received 10 mg of pravastatin or 5 mg of simvastatin once daily as the first-line treatment and were counseled to follow the National Cholesterol Education Program Step I diet. In patients assigned to the EPA group, a daily dose of 1,800 mg of pure (>98%) EPA ethyl ester was further prescribed. A total of 18,645 patients with a total cholesterol level ≥250 mg/dl at baseline, which corresponds to a low-density lipoprotein-cholesterol level ≥170 mg/dl, were examined and followed for a maximum of 5 years.
Prevention Stratum
The primary prevention stratum was defined as participants who had (1) no history of myocardial infarction (MI) or angina pectoris (AP) and neither angioplasty/stenting nor coronary artery bypass grafting up to the time point of randomization, and (2) no clinical manifestations of AP at randomization. 20 The secondary prevention stratum was defined as those without primary prevention.
Primary Endpoint
The primary endpoint of the main analysis of JELIS was the incidence of major cardiovascular events, including sudden cardiac death, fatal or nonfatal MI, and other non-fatal events including unstable AP, angioplasty, stenting, and coronary artery bypass grafting. 3,20 Because adherence to medication was a causal factor in this study, and is a highly subjective endpoint because of self-reporting by patients, the primary endpoint needed to be as objective as possible. We therefore excluded other non-fatal events from those in the main analysis; thus, sudden cardiac death and fatal/nonfatal MI were defined as the primary endpoints of this study.
Definition of Adherence
We assessed adherence to the study drug at every annual follow-up visit. Adherence to both EPA and statin was assessed for the EPA group, whereas adherence to statin alone was assessed for the control group. Next, we calculated adherence as the number of days of test-drug administration (both statin and EPA in the EPA group) divided by the number of days in the observation period for each patient. We then dichotomized adherence as good (≥80%) or poor (<80%). If a patient dropped out or died during the study, we used only (6) 779 (12) 203 (7) 660 (11) TC, mean (SD), mg/dl 275 (27) 275 (26) 276 (26) 274 (25) LDL-C, mean (SD), mg/dl 182 (30) 182 (28) 182 (30) 181 (29) Systolic BP, mean (SD), mmHg 136 (19) 136 (18) 136 (20) 136 (18) Diastolic BP, mean (SD), mmHg 80 (11) 80 (11) 80 (11) 79 (11) Values are n (%) unless otherwise noted. EPA, eicosapentaenoic acid; ADH, adherence; BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; BP, blood pressure.
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Fatty Acid (FA) Measurement
We obtained a blood sample from all patients after informed consent for measurement of plasma total FA concentrations by a central laboratory (BML Inc, Saitama, Japan). Plasma FA composition was determined by capillary gas chromatography. Briefly, plasma lipids were extracted by Folch's procedure and the FA were then methylated with boron trifluoride and methanol (with tricosanoic acid, C23:0, used as an internal standard), and methylated FA were analyzed using the Shimazu GC-17A gas chromatograph (Shimazu Corporation, Kyoto, Japan) and a BPX70 capillary column (0.25 mm ID × 30 m, SGE International Ltd, Melbourne, Victoria, Australia).
Role of the Funding Source
The sponsor of the JELIS trial (Mochida Pharmaceuticals Co Ltd Japan) was responsible for the data collection and analysis. The study concept, plan for analysis, and interpretation of the results were developed by the authors, independent of the sponsor. One of the authors (H.O.) wrote the article with full of access to the data and final responsibility for the interpretation of the data, presentation, review, and approval of the manuscript.
Statistical Analysis
Cumulative incidence of the primary endpoint was plotted using the Kaplan-Meier method for each group defined by random assignment and adherence level. Proportional hazards regression was used to estimate HR and 95% confidence intervals (CI) with adjustment for age, sex, smoking status, and comorbidity (ischemic heart disease, diabetes mellitus, and hypertension) at baseline. Trends in EPA concentration by level of adherence were examined by linear regression analysis, with levels of adherence scored as integers. Factors affecting good adherence were explored using logistic regression, including age, sex, smoking status, comorbidity, and concomitant medications as confounders. Estimated 5-year risk of the primary endpoint was determined on the basis of secondary prevention stratum using a logistic model including the above confounding variables. Analyses were performed using SAS statistical software (version 8.12, SAS Institute, Inc, Cary, NC, USA).
Results
Baseline Characteristics of Adherence
A total of 18,645 patients were randomized to either statin alone (control group) or statin plus EPA (EPA group). The average doses prescribed were pravastatin 10.0 mg daily (SD 9.1) and simvastatin 5.6 mg daily (SD 1.8). Most patients (90%) took either 10 mg pravastatin or 5 mg simvastatin. Mean follow-up was 4.7 years, with a 5-year follow-up rate of 91%. Overall adherence rate, reported as the proportion of participants taking ≥80% of the prescribed dose over the period of the study, was lower in the EPA group (66.5%) than in the control group (72.5%). Table 1 shows the characteristics of patients by good or poor adherence and control or EPA group membership. There were more smokers in the group with poor adherence (21%) than in that with good adherence (18%). In the group with good adherence as compared with poor adherence, there were more patients with ischemic heart disease (21% vs 16%) and hypertension (37% vs 32%). In addition, patients taking agents for cardiovascular diseases were more prevalent in the group with good adherence (eg, of the anti-platelets, 16% for good vs 10% for poor). Age, sex, body mass index, lipids, and blood pressure values were similar in the groups with good and poor adherence. Figure 1 shows the association between adherence and clinical outcome stratified by prevention stratum. In the stratum of primary prevention (Figure 1a) , the incidence of cardiac death or nonfatal/fatal MI in the control group was lower by 21% in patients with good adherence (HR 0.79, 95%CI 0.45-1.38, P=0.409). However, there was an almost similar incidence between patients with good and poor adherence in the EPA group (HR 0.90, 95%CI 0.49-1.66, P=0.735). Even in patients assigned to treatment with statin alone, the prognosis with good adherence to statin treatment was nearly comparable to that of patients assigned to statin plus EPA therapy. In the stratum of secondary prevention (Figure 1b) , patients in the control group with good adherence had a worse clinical outcome (HR 1.47, 95%CI 0.72-2.99, P=0.294). However, there was a much greater clinical benefit associated with adherence to treatment in the EPA group (HR 0.55, 95%CI 0.30-1.02, P=0.056). Table 2 shows the clinical outcome of EPA expressed by HR in the groups with good and poor adherence for both the primary and secondary prevention strata. In the stratum of primary prevention, the HR of taking EPA to reduce the primary endpoint was similar for patients with good (HR 0.85, P=0.508) or poor adherence (HR 0.75, P=0.400), although these risk reductions were not statistically significant. In the stratum of secondary prevention and in the group with high adherence, EPA yielded substantial risk reduction compared with statin alone (HR 0.55, 95%CI 0.34-0.88, P=0.014). Furthermore, the clinical benefit of taking EPA and statin was significantly larger in the group with good adherence than in that with poor adherence (P for interaction=0.041). Table 3 shows the relative risk of adherence and other 
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confounders in reducing the primary endpoint stratified by prevention stratum. In the primary prevention stratum, elderly men and/or patients with diabetes mellitus exhibited a significantly poor outcome (P=0.004 for age, P<0.001 for sex, P=0.001 for diabetes mellitus), although adherence was not associated with the primary endpoint (HR 1.02, 95%CI 0.93-1.12, P=0.63). On the other hand, in the secondary prevention stratum, adherence was significantly associated with prognosis (HR 090, 95%CI 0.84-0.98, P=0.016). Also, men revealed a significantly poor outcome (P=0.007). Figure 2 is a box plot of plasma EPA concentration during the follow-up period by level of adherence in the EPA and control groups. Because EPA was not taken in the control group, the concentration was similar among levels of adherence. However, in the EPA group, the concentration significantly increased with higher level of adherence (P for trend <0.0001). Patients with complete (100%) adherence had nearly twice the EPA level of patients with poor adherence (<10%). Table 4 shows the independent predictors of overall adher- Patients taking 1 or more medications for cardiovascular diseases had a 1.6-fold higher adherence rate than those on no medications (P<0.0001). On the other hand, smokers exhibited less adherence than non-smokers (OR 0.82, P<0.0001). Diabetic patients decreased a degree of adherence (OR 0.90, P=0.01). Although women exhibited slightly more adherence than men, the difference was not significant (P=0.36). Figure 3 shows the 5-year risk prediction model that was developed for the EPA group. Degree of risk according to adherence rate was estimated using a logistic model for patients with (1) no smoking habit, (2) diabetes or (3) hypertension. Women had 62% less risk than men. In both men and women, a slight increase in risk was found in patients aged 60 years or older. Comparison of the estimated risk between 100% and 0% adherence indicated that 51% risk reduction could be anticipated in patients with complete adherence compared with those who were non-adherent to treatment.
Confirmation by EPA Concentration
Factors Related to Better Adherence
5-Year Risk Prediction Model
Discussion
The JELIS 3,21 and other studies 22, 23 have demonstrated that N-3 polyunsaturated FAs, including EPA and/or DHA, are important in improving clinical outcome, as well as pathophysiological findings. The present study clearly demonstrated a strong association between adherence to medication and clinical outcome. In addition, adherence data reported by patients were shown to be quite reliable. In this section, we discuss 5 issues.
Clinical Importance of Improved Adherence to Medication
In this study, the 5-year adherence rate was relatively high, at approximately 70% on average, which may be quite high compared with the usual values because JELIS is a randomized controlled trial. However, other studies have revealed similarly high adherence rates. In the Heart and Soul Study, only 83 (8.2%) of the 1,015 participants reported non-adherence to their medications during 3.9 years of follow-up. 4 Zellner et al also reported that 89% of patients exhibited perfect or nearly perfect adherence. 24 The present study actually demonstrated that EPA significantly reduced cardiovascular risk by 45% (95%CI 12-66%, P=0.014) in patients with previous coronary artery disease (CAD) and a high degree of treatment compliance. On the other hand, EPA increased the risk by 46% (HR 1.46, 95%CI 0.65-3.28, P=0.358) in patients with a low degree of adherence. Closely looking at Figure 1b , the incidence by 3-year follow-up between the EPA and control groups seems similar. Although a large difference after 3 years might reflect a worse EPA, our clinical interpretation should have been careful enough because of the relatively small sample size after 3 years of follow-up. Furthermore, patients with good adherence were statistically significantly better in clinical outcome than those with poor adherence (P for interaction=0.041). With no previous CAD, EPA reduced the risk modestly in both patients with good and poor adherence, and there was no statistical difference in clinical outcome between good and poor adherence (P for interaction=0.691).
Beneficial effects of improved adherence to medication have also been shown in previous studies. 10,11,13,17,25, 26 A study of survivors of AMI found that the HR for those who stopped statin treatment after the event was 1.88 compared with nonusers of statins, although it was 0.84 for statin users and 0.72 for those who started taking a statin after the AMI. 27 These findings indicate that continued use of prescribed medica- 
ORIGASA H et al.
tions is required to achieve a better outcome.
Stronger Effects of Improved Adherence to Medication by Patients With Previous CAD
As shown in Table 3 , no clinical benefit was obtained by improving adherence by patients with no previous CAD (HR 1.02, 95%CI 0.93-1.12, P=0.63). However, an extraordinary effect was obtained with improved adherence by patients with a history of CAD (HR 0.90, 95%CI 0.84-0.98, P=0.016). Because this HR was computed on the basis of 10% increase in the adherence rate, the HR would be estimated as 0.81 according to a 20% increase in adherence. Now, a question might be raised about the lack of clinical benefit of adherence by patients without previous CAD. Notably, the 5-year event rate was as low as 0.6% in patients without previous CAD. 28 In such a group with a very low event rate, it may be quite difficult to improve the outcome, not only by adherence to medication but by other factors as well. On the other hand, a 5-year event rate as high as 3% was found in patients with previous CAD, 29 which is high enough that improving adherence to medication may have a marked effect in lowering it.
Credibility of Overall Medication Adherence Rate
As noted, adherence to medication refers to the extent of conformity with the recommendations for day-to-day treatment made by a provider with respect to timing, dosage, and frequency. 18 According to a survey, most studies of adherence (80%) use an objective method, including pill count (number of pills taken divided by number of pills prescribed), pharmacy refill or an electronic system, for monitoring adherence; 16 however, 20% used a subjective method, such as the clinician's impression or self-reporting by patients. Subjective methods are said to be less accurate. Our study measured adherence by direct reporting by the patients, but we were able to demonstrate the accuracy of self-reporting in relation to the EPA concentrations (Figure 2) . The overall adherence rate increased with EPA concentration. Thus, any suspicion about the adherence rate has been denied. It has been reported that patient self-reporting can provide an accurate assessment of medication adherence, 4 although there might be a difference between self-reported data and prescription records. 30 In our study, the adherence rate was determined as the number of days of supply provided during the observation period divided by the number of days in the observation period. We used 80% as a cut-off point for good or poor adherence. A survey reported that a value of 80% or higher was considered to reflect adherence in 24 studies (75%), whereas a value of 90% or higher was considered as adherent in 4 studies (13%). 31 Another survey found that a majority of studies (57%) used 75% as the cut-off, followed by 80% (33%). 17 However, no difference was found in the amount of clinical benefit with the use of different cut-off points. 17
Factors Improving Adherence
We found that independent predictors of better adherence were elderly age with comorbid conditions and/or multiple medications. On the other hand, smokers exhibited less adherence than non-smokers. This finding is consistent with a previous study of antithrombotic agents. 32 Furthermore, adherence is reported to be higher among patients with higher levels of education, 12,26 and among those who are encouraged by family members and believe in the effect of the drug they are taking. 26 These factors should be seriously considered in attempts to improve outcome.
Improving Adherence With the Assistance of Pharmacists
Poor medication adherence decreases the health benefits of drug therapy. Elderly patients with coronary risk factors frequently require treatment with multiple medications, placing them at increased risk of non-adherence. Although this study demonstrated that improving the adherence to medication led to better clinical outcomes, few studies have rigorously tested interventions aimed at improving patient adherence to prescribed medications and their effects on health outcomes. 33, 34 In this sense, the present study supports the clinical importance of adherence to drug therapy. Assistance by pharmacists is needed to enhance adherence to medication. A pharmacy care program has actually improved adherence to drug therapy. [35] [36] [37] Pharmacists have more frequent interactions with patients than family physicians, given the increasing number of community-based pharmacists in Japan.
In summary, the clinical importance of persistent adherence to prescribed medication was demonstrated by the JELIS study involving patients with hypercholesterolemia.
